spacer
home > ict > autumn 2016 > lessons learned
PUBLICATIONS
International Clinical Trials

Lessons Learned

When validating the one million data points that compose a typical Phase 3 trial, focusing on irrelevant mistakes could easily result in wasted resources. The industry’s initial response – in the form of risk-based monitoring (RBM) – detects errors and risks more efficiently, but can still expend resources on errors not pertinent to a study’s validity and, therefore, miss opportunities to define and solve critical quality issues.

What if we were to look to other industries’ strategies for risk mitigation, in order to evolve RBM into a more useful approach for protecting clinical data? One of these methodologies – namely human factor analysis (HFA) – is employed by NASA, Ford, the US Environmental Protection Agency, major airlines and several countries’ militaries to identify and mitigate human error in large, variously trained workforces. Closer to the pharmaceutical sector, human factors are the core to the foundation training by the WHO in its education on patient safety (1). HFA uses uniquely structured datasets to show underlying behaviours that are otherwise difficult for humans to sense or reconstruct but are, ultimately, the root cause of an incident.

Consider a site that has multiple issues with informed consent. A traditional monitoring approach would log a problem, potentially announce the site as high risk and deploy general retraining on informed consent. Instead, using HFA allows one to look for trends in the data and classify what they revealed in predetermined categories; for instance, consent errors became more frequent after that site had enrolled 100 or more patients. To mitigate risk, the project team could perhaps limit the site to no more than 75 patients and provide additional investigator support focusing on resource allocation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Clara Heering is Senior Vice President of Clinical Risk and Data Management at ICON, and has over 20 years’ experience in clinical research, which spans both CRO and pharma industries. Clara's previous experience includes 16 years at Pfizer and two years as Research Fellow at Harvard Medical School, US. She holds a degree in Risk Management and in Medical Biology.
spacer
Clara Heering
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement